| ²é¿´: 3113 | »Ø¸´: 4 | ||
ÓÒ°¶½ð³æ (ÕýʽдÊÖ)
|
[ÇóÖú]
canertinib¿¨ÄÎÌæÄáÕâ¸ö¿¹Ö×ÁöÒ©ÎïÓÐûÓÐÉÏÊУ¿
|
| canertinib¿¨ÄÎÌæÄáÕâ¸ö¿¹Ö×ÁöÒ©ÎïÓÐûÓÐÉÏÊУ¿Èç¹ûÓУ¬Ê²Ã´Ê±ºò£¿ |
» ²ÂÄãϲ»¶
ʹÓÃMolAICal½øÐжàëÄÐéÄâɸѡ½Ì³Ì-ͬÑùÊÊÓÃÓÚµ°°×ÖʺͺËËáµÄÐéÄâɸѡ
ÒѾÓÐ1È˻ظ´
ʹÓÃMolAICal¼ÆËãÒ©Îﻯѧ¹ýÂËÆ÷MCFs¼°MCE-18ÃèÊö·û
ÒѾÓÐ0È˻ظ´
Ò©ÀíѧÂÛÎÄÈóÉ«/·ÒëÔõôÊÕ·Ñ?
ÒѾÓÐ266È˻ظ´
ʹÓÃMolAICal·¢ÏÖµ°°×ÊÜÌåDZÔڵĻîÐÔ¿Ú´ü¼°Î»µã
ÒѾÓÐ0È˻ظ´
»ªÀíҩѧѧ˶Çóµ÷¼Á£¬×Ü·Ö324
ÒѾÓÐ0È˻ظ´
292ҩѧµ÷¼Á
ÒѾÓÐ1È˻ظ´
°ÄÃÅÀí¹¤´óѧÈ˹¤ÖÇÄÜÒ©Îï·¢ÏÖÖÐÐÄÕÐÊÕ2026¼¶²©Ê¿Ñо¿Éú£¨ÉêÇë-¿¼ºËÖÆ£©
ÒѾÓÐ10È˻ظ´
ʹÓÃMolAICalÉú³ÉС·Ö×ÓCHARMMÁ¦³¡ÍØÆËºÍ²ÎÊýÎļþ
ÒѾÓÐ0È˻ظ´
NSCLCÄÔ×ªÒÆÖ×ÁöÄ£ÐÍ
ÒѾÓÐ0È˻ظ´
CHP-134Õâ¸öϸ°ûϵÄÄÀïÓУ¿
ÒѾÓÐ0È˻ظ´
» ±¾Ö÷ÌâÏà¹Ø¼ÛÖµÌùÍÆ¼ö£¬¶ÔÄúͬÑùÓаïÖú:
¡¾¿Î¼þ¡¿Ö×Áö¶¯ÎïÄ£ÐͺͿ¹Ö×ÁöÒ©ÎïµÄÑо¿·½·¨
ÒѾÓÐ58È˻ظ´
ÇóÖúÀ´ÄÇÌæÄáÉÏÊÐÐÅÏ¢£¿
ÒѾÓÐ12È˻ظ´
¹ØÓÚÌæÄáÀ࿹Ö×ÁöÒ©ÎïµÄÉú²úÌõ¼þ
ÒѾÓÐ3È˻ظ´
ÎÒ¹ú¡°ÌæÄáÀࡱ£¨ÀÒ°±ËἤøÒÖÖÆ¼Á£©¿¹Ö×ÁöÒ©µÄÊг¡ÏÖ×´
ÒѾÓÐ15È˻ظ´
¡¾´ð°¸¡¿Ó¦Öú»ØÌû
¡ï ¡ï ¡ï
zhoudeli(½ð±Ò+1): ¶àл²ÎÓë¡£ 2011-12-25 17:47:35
mouse103: Ó¦ÖúÖ¸Êý+1 2012-05-20 05:30:39
ÓÒ°¶: ½ð±Ò+2, ¡ïÓаïÖú 2012-06-01 22:12:38
zhoudeli(½ð±Ò+1): ¶àл²ÎÓë¡£ 2011-12-25 17:47:35
mouse103: Ó¦ÖúÖ¸Êý+1 2012-05-20 05:30:39
ÓÒ°¶: ½ð±Ò+2, ¡ïÓаïÖú 2012-06-01 22:12:38
|
As no development has been reported for some time, this program is assumed to be discontinued. Pfizer (formerly by Warner-Lambert), under license from the University of Auckland, was developing canertinib (CI-1033, PD-0183805), a water soluble, orally-available analog of PD-169414, an EGFR tyrosine kinase inhibitor, as a potential treatment for cancer [427113]. By January 2000, phase I trials were underway [353284], [352930]. In September 2001, the drug was reported to be in phase II trials [427113], [429152]; these trials were ongoing in June 2004 [542422]. |
2Â¥2011-12-25 16:13:43
ÓÒ°¶
½ð³æ (ÕýʽдÊÖ)
- Ó¦Öú: 0 (Ó×¶ùÔ°)
- ½ð±Ò: 2872.5
- É¢½ð: 50
- Ìû×Ó: 400
- ÔÚÏß: 62.2Сʱ
- ³æºÅ: 946928
- ×¢²á: 2010-01-22
- ÐÔ±ð: MM
- רҵ: Óлú»¯¹¤
3Â¥2011-12-25 17:27:13
ashuai078201
ͳæ (СÓÐÃûÆø)
- Ó¦Öú: 6 (Ó×¶ùÔ°)
- ½ð±Ò: 128.5
- É¢½ð: 3
- Ìû×Ó: 63
- ÔÚÏß: 5.7Сʱ
- ³æºÅ: 1214346
- ×¢²á: 2011-02-26
- ÐÔ±ð: GG
- רҵ: Ò©Îﻯѧ
¡¾´ð°¸¡¿Ó¦Öú»ØÌû
¡ï
¸Ðл²ÎÓ룬ӦÖúÖ¸Êý +1
mouse103: ½ð±Ò+1, лл²ÎÓë 2012-05-20 05:31:16
¸Ðл²ÎÓ룬ӦÖúÖ¸Êý +1
mouse103: ½ð±Ò+1, лл²ÎÓë 2012-05-20 05:31:16
|
ÓÉÓÚûÓз¢Õ¹ÒѾ±¨µÀÁËÒ»¶Îʱ¼ä£¬Õâ¸ö·½°¸ÊǼÙÉèÖÕÖ¹¡£ ¸ø·ÒëÏ |
4Â¥2011-12-27 15:10:41
chem_gd
½ð³æ (³õÈëÎÄ̳)
- Ó¦Öú: 1 (Ó×¶ùÔ°)
- ½ð±Ò: 798.8
- ºì»¨: 1
- Ìû×Ó: 18
- ÔÚÏß: 7.1Сʱ
- ³æºÅ: 1503707
- ×¢²á: 2011-11-22
- רҵ: »¯Ñ§ÉúÎïѧÓëÉúÎïÓлú»¯Ñ§
¡¾´ð°¸¡¿Ó¦Öú»ØÌû
¡ï
¸Ðл²ÎÓ룬ӦÖúÖ¸Êý +1
mouse103: ½ð±Ò+1, лл²ÎÓë 2012-05-20 05:31:33
¸Ðл²ÎÓ룬ӦÖúÖ¸Êý +1
mouse103: ½ð±Ò+1, лл²ÎÓë 2012-05-20 05:31:33
| ûÓÐÉÏÊС£»ÔÈð»¹ÓкóÐøµÄÀàËÆ·Ö×Ó£¬ÒÔ¼°Boehringer IngelheimÒ²ÓÐÀàËÆ·Ö×Ó£¬µ«ÊÇЧ¹û²»ÊǺܺᣠ|
5Â¥2012-04-02 11:11:18









»Ø¸´´ËÂ¥
ÓÒ°¶